No abstract

Background: Adverse Drug Reactions (ADR’s) to anti-TB drugs might contribute to the extension of treatment period, final termination, drug resistance and treatment failure as Anti-TB medications are the main stay treatment in Tuberculosis. These ADR’s may cause unintended interruption of treatment which may pose a challenge in TB management. Aim: This study aims to explore and observe adverse reactions of 1st line antitubercular drugs in DOTS treatment. Methodology: This is a analysis of ADRs of antitubercular drugs that were reported to ADR monitoring centre (AMC), SDSTRC and RGICD ,Bangalore either by spontaneous reporting or found by active surveillance methods. This study was for about 32 months. During this period all the ADRs caused by antitubercular drugs reported to the AMC were collected and classified based on WHO causality assessment. Later all those data were analyzed and results were generated Results: A total of 507 ADR’s were reported and out of which the majority of ADR’s were reported in adult population (45%). Based on gender, Male had a higher incidence of ADR (324, 63.9%). Based on WHO causality assessment scale, 69.4% of ADRs were ‘possible’ followed by 25.2% being ‘probable’ and 4.1% being ‘certain’. Conclusion: Monitoring of patients on Anti tubercular treatment with early identification and appropriate management of ADR becomes very essential. The timely and aggressive management of adverse effects of anti-tubercular drugs greatly facilitates patient adherence.

No abstract

Cardiovascular disorders have been one of the mainstay causes for the estimated rise in the incidences of mortality. In earlier times, treatment approach was initiated with statin therapy even though there were high reports of adverse events and failure to attain the target lipid concentration. In 2003, Proprotein Convertase subtilisin/kexin 9 was found to be responsible for the degradation and inactivation of LDL receptors. Ever since the concept was introduced, many researches have been conducted in this field for a better control in lipid management. Alirocumab was approved by FDA in the year 2015 as a PCSK9 inhibitor indicated for heterozygous familial hypercholesterolemia. The purpose of this review is to compile the available information on the LDL-C reduction capacity of Alirocumab in combination with statins and simultaneous cardiovascular risk reduction. It also aims at providing an evidential safety data associated with Alirocumab use. Alirocumab is presently available in doses of 75 and 150mg subcutaneous injections once every two weeks. It is a monoclonal antibody directed against PCSK9 and evidential data provides an estimate of about 54% reduction in LDL-C concentrations. The application of Alirocumab as add on therapy to statins is the area of interest and the data suggests that there is a significant higher rate of LDL-C reductions in turn leading to a noteworthy cardiovascular risk reduction. However the appropriate dose of statins to incorporate a PCSK9 inhibitor requires further hypotheses. Additionally the safety profile of Alirocumab was found to be comparable with placebo or the control.